Mexico’s Cofepris granted the world’s first sanitary registration for an RNA-based biofungicide on August 12, 2026, a move immediately paired with GreenLight Biosciences' announcement of a US$100 million plant investment in Mexico City. This regulatory approval directly facilitates a significant capital expansion for the biotech firm into Latin American agricultural markets.
The newly approved product targets powdery mildew in grapes, caused by Erysiphe necator. GreenLight Biosciences also has an RNA acaricide for spider mites, affecting crops like avocado and strawberry, still under evaluation by Cofepris. The company hasn't disclosed efficacy figures for that second product.
Regulators described the biofungicide's mechanism as one that "turns off the fungus’s gene" needed for survival. Officials claim the RNA acts only on the target fungus and degrades naturally in soil, water, and fruit. The approval involved coordination with Senasica and Semarnat, demonstrating a unified state effort to greenlight the new technology.
Opening New Markets
GreenLight Biosciences founder and CEO Andrey Zarur announced the manufacturing plans concurrently with the regulatory approval. This synchronized announcement underscores the direct link between state action and corporate investment. The specific commercial product name remains undisclosed.
This approval isn't just about one product; it's framed as a fundamental shift in regulatory thinking about crop protection. It signals Mexico's explicit openness to biotech innovation in agriculture, provided the science meets regulatory standards. This precedent could encourage other corporations to bring similar products to the region, intensifying the drive for market share.
The move is expected to pressure other Latin American regulators to develop RNA-based crop-protection frameworks. Countries like Argentina, Brazil, and Chile, with their large, export-driven farm sectors, could face demands to fast-track similar approvals if the technology proves profitable in Mexican fields. This creates a regulatory race to the bottom, prioritizing corporate access over independent evaluation.
Capital's 'Solutions'
Conventional chemical fungicides are described as broad-spectrum tools that harm beneficial fungi, disrupt soil ecosystems, and leave residues. Regulators and consumers are increasingly critical of these older methods. The RNA biofungicide is presented as a solution to these problems, promising to help growers maintain high yields while lowering environmental impact. This framing positions a corporate product as the answer to ecological damage often caused by industrial agriculture itself.
GreenLight Biosciences claims local production in Mexico City will support local supply chains and create local jobs. This narrative of local benefit often accompanies large foreign investments, serving to legitimize capital's entry. The company also suggests it will shorten the distance between production and application for growers across North and Central America, streamlining its distribution network.
The U.S. EPA registered the first sprayable RNA pesticide in 2023, indicating that Mexico's decision is part of a broader, international trend of regulatory bodies clearing the path for biotech capital. This global coordination among states facilitates the expansion of corporate control over agricultural inputs. The approval marks a new phase in the commodification of agricultural solutions, further entrenching corporate power in food systems.